Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Référence presse grand public
Cité 5 fois dans les médias — pédagogie reconnue
7ans d'exercice (thèse 2019)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Direction : Céline Bourgier, Nathalie Bonnefoy
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer
2026ArticleInternational Journal of Cancer
Robustness of radiomics features on 0.35 T magnetic resonance imaging for magnetic resonance-guided radiotherapy
2024ArticlePhysics and Imaging in Radiation Oncology
Towards Privacy-first Manufacturing Data Exchange Platform
2023CongrèsSOICT 2023: The 12th International Symposium on Information and Communication Technology
Non-contact monitoring of soda-lime glass surface changes by its LWIR apparent emissivity: Possibilities and limitations
2023ArticleNDT & E International
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
2023ArticleBMC Cancer
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
2023ArticleJournal of Clinical Medicine
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study
2023ArticleCancers
Management of thermal drift of bolometric infrared cameras: limits and recommendations
2023ArticleQuantitative InfraRed Thermography Journal
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Actu.fr · 16/05/2024
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxONnlOcVEzektVWlE0WWFoMHJBM0RCbEFqYlZtZm9XS2lWZ2lxNGlsbkhRVDRvdERHaEdLaWhLczRlSXkzY2s2dzM5N2pIQ0x3U3drcmo2UTFwRF9jdUVYT29BTlhMT1ZNS2VxOTRodEl4WTdtb0U4X0ZHdEtDWU8wUVJ2OGxuX0ZkbGtKd1VrS1BaeWc1b3pnTzBGd3F4QmJNS2psVjh5bW1mcVU?oc=5" target="_bla
📰 Midi Libre · 15/05/2024
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxQQjNBQTFSX0ljYmFKbTE3dFlWQW04LTR4SGl3VTFLZmN1WE9lbVF2VUtNOENZVnJfa2ZoalBxT1JPMHo1OVBucVc4VDByNHJ4OWN5NS15SHVZLWtJaDJwMHgyMXZJV3g3VHdOSDcyZ2lrYWJnNUV2Qm5VTnpSR0xyTTVaQkVfWE9aYjgzcTFEQjFKc0EybkFzMjV1U1BUcWhvQTA0eXdaWE9vb3hqUm8xMERFMDRZdk5pNH
📰 MNP.ca · 03/06/2021
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9UNHY4VFVKRURMZnpXTXptTDgwTVRlSkNtMEh6MjJRblhLN1BHalVlelloVUh2TnhtaFdmekxFT1FYZXV0WUROZnA2VFdVYjk3Y2c1ZUZrUG9DbC0tZmxHeQ?oc=5" target="_blank">Pierre Olivier Rious</a> <font color="#6f6f6f">MNP.ca</font>
📰 Ouest-France · 21/04/2020
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQT092ck4zR1lIXzZpX0t4NEdISEd6MEVqb1pBem9QU0h4Y0dEMTJtUjRJS3ozSUNoQ2R2ZHItY01nVWNpdkFVazdxSkI0ODZOMzRBa05rNjNmRGk3TkxTUG5GdmJqeTJreDg0T0J5UUR6ci03TDVRVnZ4bWd1ZDZ2dGdvWVZkQVNuWHdobkQ2bERrY3ZOTldsMlZFM05hdDFLc3A1NWlXNWduclUzR1kwS29oUXY5aWNZ?o
📰 Ouest-France · 28/02/2013
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWtCR1NEcTZGTnpucHBmOGRXS1JWTGx1dFN0anNOYWhwUjRoRi1PeWN0d3VheGlsRThwc1U4bVRoR1hSVVVGWGNieFExQ2xidWZmV3RvNlQ4dndWbXFmWXY3NVpYYVNzRC1YTDJVMENrbjlkUkU0U0U3TWVRblJhaTNZZ3FGZHBxcjdPSm51UnNFZF9INHJDelJHOG50WW00ekdtVGhHOGtOQQ?oc=5" target="_blan
Frontiers in oncology · 2022
IntroductionStereotactic MR-guided adaptive radiotherapy (SMART) is an attractive modality of radiotherapy for pancreatic tumors. The objectives of this prospective registry study were to report the dosimetric benefits of daily adaptation of SMART and the first clinical results in pancreatic tumors.Materials and MethodsAll patients treated in our center with SMART for a pancreatic tumor were included. Patients were planned for five daily-adapted fractions on consecutive days. Endpoints were acute toxicities, late toxicities, impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC) rate, distant metastasis-free survival (DMFS), and overall survival (OS).ResultsThirty consecutive patients were included between October 2019 and April 2021. The median dose prescription was 50 Gy. No patient presented grade &gt; 2 acute toxicities. The most frequent grade 1–2 toxicities were asthenia (40%), abdominal pain (40%), and nausea (43%). Daily adaptation significantly improved planning target volume (PTV) and gross tumor volume (GTV) coverage and OAR sparing. With a median follow-up of 9.7 months, the median OS, 6-month OS, and 1-year OS were 14.1 months, 89% (95% CI: 70%–96%), and 75% (95% CI: 51%–88%), respectively, from SMART completion. LC at 6 months and 1 year was respectively 97% (95% CI: 79–99.5%) and 86% (95% CI: 61%–95%). There were no grade &gt; 2 late toxicities. With a median follow-up of 10.64 months, locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC) patients (22 patients) had a median OS, 6-month OS, and 1-year OS from SMART completion of 14.1 months, 76% (95% CI: 51%–89%), and 70% (95% CI: 45%–85%), respectively. Nine patients underwent surgical resection (42.1% of patients with initial LAPC and 33.3% of patients with BRPC), with negative margins (R0). Resected patients had a significantly better OS as compared to unresected patients (p = 0.0219, hazard ratio (HR) = 5.78 (95% CI: 1.29–25.9)).ConclusionSMART for pancreatic tumors is feasible without limiting toxicities. Daily adaptation demonstrated a benefit for tumor coverage and OAR sparing. The severity of observed acute and late toxicities was low. OS and LC rates were promising. SMART achieved a high secondary resection rate in LAPC patients. Surgery after SMART seemed to be feasible and might increase OS in these patients.
Cancers · 2022
Introduction: Stereotactic MR-guided Adaptive RadioTherapy (SMART) is a novel process to treat pancreatic tumors. We present an update of the data from our prospective registry of SMART for pancreatic tumors. Materials and methods: After the establishment of the SMART indication in a multidisciplinary board, we included all patients treated for pancreatic tumors. Primary endpoints were acute and late toxicities. Secondary endpoints were survival outcomes (local control, overall survival, distant metastasis free survival) and dosimetric advantages of adaptive process on targets volumes and OAR. Results: We included seventy consecutive patients in our cohort between October 2019 and April 2022. The prescribed dose was 50 Gy in 5 consecutive fractions. No severe acute SMART related toxicity was noted. Acute and late Grade ≤ 2 gastro intestinal were low. Daily adaptation significantly improved PTV and GTV coverage as well as OAR sparing. With a median follow-up of 10.8 months since SMART completion, the median OS, 6-months OS, and 1-year OS were 20.9 months, 86.7% (95% CI: (75–93%), and 68.6% (95% CI: (53–80%), respectively, from SMART completion. Local control at 6 months, 1 year, and 2 years were, respectively, 96.8 % (95% CI: 88–99%), 86.5 (95% CI: 68–95%), and 80.7% (95% CI: 59–92%). There was no grade > 2 late toxicities. Locally Advanced Pancreatic Cancers (LAPC) and Borderline Resectable Pancreatic Cancers (BRPC) patients (52 patients) had a median OS, 6-months OS, and 1-year OS from SMART completion of 15.2 months, 84.4% (95% CI: (70–92%)), and 60.5% (95% CI: (42–75%)), respectively. The median OS, 1-year OS, and 2-year OS from initiation of induction chemotherapy were 22.3 months, 91% (95% CI: (78–97%)), and 45.8% (95% CI: (27–63%)), respectively. Twenty patients underwent surgical resection (38.7 % of patients with initially LAPC) with negative margins (R0). Conclusion: To our knowledge, this is the largest series of SMART for pancreatic tumors. The treatment was well tolerated with only low-grade toxicities. Long-term OS and LC rates were achieved. SMART achieved high secondary resection rates in LAPC patients.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024 · Video-Audio Media
Colombo PE, Druet C, Mourregot A, Riou O, et al.
Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2023 · Journal Article
Riou O, Gourgou S, Conroy T
Journal of clinical medicine · 2022 · Journal Article
Michalet M, Bettaïeb O, Khalfi S, Ghorbel A, et al.
Travel medicine and infectious disease · 2021 · Letter
Moury PH, Gourinat AC, Riou O, Laumond S, et al.
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2019 · Journal Article
Druet X, Acosta Sanchez E, Soleakhena K, Laprie A, et al.
Oncotarget · 2018 · Journal Article
Bourgier C, Castan F, Riou O, Nguyen TD, et al.
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2017 · Journal Article
Bedos L, Riou O, Aillères N, Braccini A, et al.
EBioMedicine · 2015 · Clinical Trial
Azria D, Riou O, Castan F, Nguyen TD, et al.
International journal of radiation oncology, biology, physics · 2014 · Clinical Trial, Phase I
Azria D, Riou O, Rebillard X, Thezenas S, et al.
Journal of applied clinical medical physics · 2013 · Comparative Study
Riou O, Regnault de la Mothe P, Azria D, Aillères N, et al.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists · 2013 · Clinical Trial
Riou O, Laliberté B, Azria D, Menkarios C, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025 · Journal Article
Buchalet C, Riou O, Colin R, Valdenaire S, et al.
International journal of radiation oncology, biology, physics · 2025 · Journal Article
Michalet M, Valenzuela G, Nougaret S, Tardieu M, et al.
Physics and imaging in radiation oncology · 2024 · Journal Article
Michalet M, Valenzuela G, Debuire P, Riou O, et al.
Journal of clinical medicine · 2023 · Journal Article
Bordeau K, Michalet M, Keskes A, Valdenaire S, et al.
Cancers · 2022 · Journal Article
Bordeau K, Michalet M, Keskes A, Valdenaire S, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · Journal Article
Michalet M, Ronchin P, Reynaud T, Demogeot N, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · Journal Article
Riou O, Fenoglietto P, Jarlier M, Prunaretty J, et al.
BMC cancer · 2023 · Clinical Trial Protocol
Modesto A, Tougeron D, Tremolières P, Ronchin P, et al.
Radiation oncology (London, England) · 2015 · Journal Article
Riou O, Fenoglietto P, Bourgier C, Lauche O, et al.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2023 · Journal Article
Bordeau K, Michalet M, Dorion V, Keskes A, et al.
Cancers · 2022 · Journal Article
Michalet M, Riou O, Cottet-Moine J, Castan F, et al.
Advances in radiation oncology · 2021 · Journal Article
Michalet M, Riou O, Valdenaire S, Debuire P, et al.
Frontiers in oncology · 2022 · Journal Article
Michalet M, Bordeau K, Cantaloube M, Valdenaire S, et al.